ECM
ADVM

Endurant Capital Management’s Adverum Biotechnologies ADVM Stock Holding History

Endurant Capital Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-21,482
Closed -$2.48M – 54
2019
Q4 		$2.48M Buy
+21,482
New +$1.89M 0.78% 32
2019
Q3 		– Sell
-3,187
Closed -$379K – 50
2019
Q2 		$379K Buy
+3,187
New +$264K 0.15% 50
2018
Q4 		– Sell
-16,884
Closed -$1.02M – 52
2018
Q3 		$1.02M Buy
+16,884
New +$948K 0.45% 46

Other funds holding ADVM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Endurant Capital Management's ADVM Position: Q1 2020 in Review

Endurant Capital Management sold out of Adverum Biotechnologies (ADVM) in Q1 2020, closing a stake of 21,482 shares — an estimated $2.48M sold.

Endurant Capital Management first reported a position in ADVM in Q3 2018 and held it in 3 quarters. The position peaked at $2.48M in Q4 2019. 126 funds tracked by Wall St. Rank hold ADVM as of Q1 2020.

  • Endurant Capital Management reported no remaining Adverum Biotechnologies position as of Q1 2020 after selling out during the quarter.
  • Endurant Capital Management sold 21,482 Adverum Biotechnologies shares in Q1 2020, an estimated $2.48M.
  • Endurant Capital Management first reported a position in Adverum Biotechnologies in Q3 2018 and held it in 3 quarters.
  • Endurant Capital Management's Adverum Biotechnologies position peaked at $2.48M in Q4 2019.
  • 126 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2020.

Based on Endurant Capital Management's 13F filing for Q1 2020, filed 15 May 2020.